A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic

Clinical Trial Description

This study will have two 16-day treatment periods (four escalating doses or matching placebo at four days interval) separated by a 10 to 14-day washout period. There will be a 14-day follow-up period. ;

Study Design

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05570981` - A Comprehensive Evaluation of the Impact of ATP on Laryngeal Symptoms, Hypersensitivity and Function
Completed	`NCT01703923` - An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough	Phase 2
Completed	`NCT02993822` - A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough	Phase 2

See also

Status

Clinical Trial

Phase

Recruiting

NCT05570981 - A Comprehensive Evaluation of the Impact of ATP on Laryngeal Symptoms, Hypersensitivity and Function

Completed

NCT01703923 - An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough

Phase 2

Completed

NCT02993822 - A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03979638
Study type	Interventional
Source	Bellus Health Inc
Contact
Status	Terminated
Phase	Phase 2
Start date	July 10, 2019
Completion date	April 23, 2020

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough — RELIEF

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms